Loss in life expectancy and gain in life years as measures of cancer impact.

Cancer survival Inequalities Life expectancy Population-based studies Statistical methods

Journal

Cancer epidemiology
ISSN: 1877-783X
Titre abrégé: Cancer Epidemiol
Pays: Netherlands
ID NLM: 101508793

Informations de publication

Date de publication:
06 2019
Historique:
received: 13 02 2019
revised: 12 04 2019
accepted: 16 04 2019
pubmed: 6 5 2019
medline: 28 2 2020
entrez: 5 5 2019
Statut: ppublish

Résumé

There are a broad range of survival-based metrics that are available to report from cancer survival studies, with varying advantages and disadvantages. A combination of metrics should be considered to improve comprehensibility and give a fuller understanding of the impact of cancer. In this article, we discuss the utility of loss in life expectancy and gain in life years as measures of cancer impact, and to quantify differences across population groups. These measures are simple to interpret, have a real-world meaning, and evaluate impact over a life-time horizon. We illustrate the use of the loss in life expectancy measures through a range of examples using data on women diagnosed with cancer in England. We use four different examples across a number of tumour types to illustrate different uses of the metrics, and highlight how they can be interpreted and used in practice in population-based oncology studies. Extensions of the measures conditional on survival to specific times after diagnosis can be used to give updated prognosis for cancer patients. Furthermore, we show how the measures can be used to understand the impact of population differences seen across patient groups. We believe that these under-used, and relatively easy to calculate, measures of overall impact can supplement reporting of cancer survival metrics and improve the comprehensibility compared to the metrics typically reported.

Identifiants

pubmed: 31054465
pii: S1877-7821(19)30030-X
doi: 10.1016/j.canep.2019.04.005
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

168-173

Subventions

Organisme : Cancer Research UK
ID : C1483/A18262
Pays : United Kingdom

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Mark J Rutherford (MJ)

Department of Health Sciences, University of Leicester, UK. Electronic address: mark.rutherford@le.ac.uk.

T M-L Andersson (TM)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Sweden.

Magnus Björkholm (M)

Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.

Paul C Lambert (PC)

Department of Health Sciences, University of Leicester, UK; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH